- Record: found
- Abstract: not found
- Article: not found
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
Sabine Hombach-Klonisch ,
Maryam Mehrpour ,
Shahla Shojaei ,
Craig Harlos ,
Marshall Pitz ,
Ahmed Hamai ,
Krzysztof Siemianowicz ,
Wirginia Likus ,
Emilia Wiechec ,
Brian D. Toyota ,
Reyhane Hoshyar ,
Amir Seyfoori ,
Zahra Sepehri ,
Sudharsana R. Ande ,
Forough Khadem ,
Mohsen Akbari ,
Adrienne M. Gorman ,
Afshin Samali ,
Thomas Klonisch ,
Saeid Ghavami
April 2018
April 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment
of brain tumors remains a challenge. This is particularly true for the most frequent
and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival
time of GB patients remains only approximately 15months. The alkylating drug temozolomide
(TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and
unfolded protein response (UPR). Here, we review these cellular mechanisms and their
contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on
TMZ chemoresistance in glioma stem cells and GB.